Development of a High-Throughput Cytometric Screen to Identify Anti-Wolbachia Compounds: The Power of Public–Private Partnership

Rachel Clare; Roger Clark; Catherine Bardelle; Paul Harper; Matthew Collier; Kelly Johnston; Helen Plant; Darren Plant; Eileen McCall; Barton E. Slatko; Lindsey Cantin; Bo Wu; Louise Ford; David Murray; Kirsty Rich; Mark Wigglesworth; Mark Taylor; Steve Ward

doi:10.1177/2472555219838341

Development of a High-Throughput Cytometric Screen to Identify Anti-Wolbachia Compounds: The Power of Public–Private Partnership

Rachel Clare
, Roger Clark
, Catherine Bardelle
, Paul Harper
, Matthew Collier
, Kelly Johnston
, Helen Plant
, Darren Plant
, Eileen McCall
, Barton E. Slatko
, Lindsey Cantin
, Bo Wu
, Louise Ford
, David Murray
, Kirsty Rich
, Mark Wigglesworth
, Mark Taylor
, Steve Ward

AstraZeneca
New England Biolabs

Research output: Contribution to journal › Article › peer-review

10 Citations (Scopus)

Abstract

The Anti-Wolbachia (A·WOL) consortium at the Liverpool School of Tropical Medicine (LSTM) has partnered with the Global High-Throughput Screening (HTS) Centre at AstraZeneca to create the first anthelmintic HTS for neglected tropical diseases (NTDs). The A·WOL consortium aims to identify novel macrofilaricidal drugs targeting the essential bacterial symbiont (Wolbachia) of the filarial nematodes causing onchocerciasis and lymphatic filariasis. Working in collaboration, we have validated a robust high-throughput assay capable of identifying compounds that selectively kill Wolbachia over the host insect cell. We describe the development and validation process of this complex, phenotypic high-throughput assay and provide an overview of the primary outputs from screening the AstraZeneca library of 1.3 million compounds.

Original language	English
Pages (from-to)	537-547
Number of pages	11
Journal	SLAS Discovery
Volume	24
Issue number	5
Early online date	8 Apr 2019
DOIs	https://doi.org/10.1177/2472555219838341
Publication status	Published - 1 May 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

acumen
high-throughput screening
lymphatic filariasis
neglected tropical diseases
onchocerciasis
phenotypic screening
Wolbachia

Access to Document

10.1177/2472555219838341Licence: CC BY-NC-ND

Clare et al 2019Accepted author manuscript, 1.18 MBLicence: CC BY

Cite this

Clare, R., Clark, R., Bardelle, C., Harper, P., Collier, M., Johnston, K., Plant, H., Plant, D., McCall, E., Slatko, B. E., Cantin, L., Wu, B., Ford, L., Murray, D., Rich, K., Wigglesworth, M., Taylor, M., & Ward, S. (2019). Development of a High-Throughput Cytometric Screen to Identify Anti-Wolbachia Compounds: The Power of Public–Private Partnership. SLAS Discovery, 24(5), 537-547. https://doi.org/10.1177/2472555219838341

@article{607b9177dafa4d13a35a33457abf90f3,

title = "Development of a High-Throughput Cytometric Screen to Identify Anti-Wolbachia Compounds: The Power of Public–Private Partnership",

abstract = "The Anti-Wolbachia (A·WOL) consortium at the Liverpool School of Tropical Medicine (LSTM) has partnered with the Global High-Throughput Screening (HTS) Centre at AstraZeneca to create the first anthelmintic HTS for neglected tropical diseases (NTDs). The A·WOL consortium aims to identify novel macrofilaricidal drugs targeting the essential bacterial symbiont (Wolbachia) of the filarial nematodes causing onchocerciasis and lymphatic filariasis. Working in collaboration, we have validated a robust high-throughput assay capable of identifying compounds that selectively kill Wolbachia over the host insect cell. We describe the development and validation process of this complex, phenotypic high-throughput assay and provide an overview of the primary outputs from screening the AstraZeneca library of 1.3 million compounds.",

keywords = "acumen, high-throughput screening, lymphatic filariasis, neglected tropical diseases, onchocerciasis, phenotypic screening, Wolbachia",

author = "Rachel Clare and Roger Clark and Catherine Bardelle and Paul Harper and Matthew Collier and Kelly Johnston and Helen Plant and Darren Plant and Eileen McCall and Slatko, \{Barton E.\} and Lindsey Cantin and Bo Wu and Louise Ford and David Murray and Kirsty Rich and Mark Wigglesworth and Mark Taylor and Steve Ward",

year = "2019",

month = may,

day = "1",

doi = "10.1177/2472555219838341",

language = "English",

volume = "24",

pages = "537--547",

journal = "SLAS Discovery",

issn = "2472-5552",

publisher = "Society for Laboratory Automation and Screening (SLAS)",

number = "5",

}

Clare, R, Clark, R, Bardelle, C, Harper, P, Collier, M, Johnston, K, Plant, H, Plant, D, McCall, E, Slatko, BE, Cantin, L, Wu, B, Ford, L, Murray, D, Rich, K, Wigglesworth, M, Taylor, M & Ward, S 2019, 'Development of a High-Throughput Cytometric Screen to Identify Anti-Wolbachia Compounds: The Power of Public–Private Partnership', SLAS Discovery, vol. 24, no. 5, pp. 537-547. https://doi.org/10.1177/2472555219838341

TY - JOUR

T1 - Development of a High-Throughput Cytometric Screen to Identify Anti-Wolbachia Compounds: The Power of Public–Private Partnership

AU - Clare, Rachel

AU - Clark, Roger

AU - Bardelle, Catherine

AU - Harper, Paul

AU - Collier, Matthew

AU - Johnston, Kelly

AU - Plant, Helen

AU - Plant, Darren

AU - McCall, Eileen

AU - Slatko, Barton E.

AU - Cantin, Lindsey

AU - Wu, Bo

AU - Ford, Louise

AU - Murray, David

AU - Rich, Kirsty

AU - Wigglesworth, Mark

AU - Taylor, Mark

AU - Ward, Steve

PY - 2019/5/1

Y1 - 2019/5/1

N2 - The Anti-Wolbachia (A·WOL) consortium at the Liverpool School of Tropical Medicine (LSTM) has partnered with the Global High-Throughput Screening (HTS) Centre at AstraZeneca to create the first anthelmintic HTS for neglected tropical diseases (NTDs). The A·WOL consortium aims to identify novel macrofilaricidal drugs targeting the essential bacterial symbiont (Wolbachia) of the filarial nematodes causing onchocerciasis and lymphatic filariasis. Working in collaboration, we have validated a robust high-throughput assay capable of identifying compounds that selectively kill Wolbachia over the host insect cell. We describe the development and validation process of this complex, phenotypic high-throughput assay and provide an overview of the primary outputs from screening the AstraZeneca library of 1.3 million compounds.

AB - The Anti-Wolbachia (A·WOL) consortium at the Liverpool School of Tropical Medicine (LSTM) has partnered with the Global High-Throughput Screening (HTS) Centre at AstraZeneca to create the first anthelmintic HTS for neglected tropical diseases (NTDs). The A·WOL consortium aims to identify novel macrofilaricidal drugs targeting the essential bacterial symbiont (Wolbachia) of the filarial nematodes causing onchocerciasis and lymphatic filariasis. Working in collaboration, we have validated a robust high-throughput assay capable of identifying compounds that selectively kill Wolbachia over the host insect cell. We describe the development and validation process of this complex, phenotypic high-throughput assay and provide an overview of the primary outputs from screening the AstraZeneca library of 1.3 million compounds.

KW - acumen

KW - high-throughput screening

KW - lymphatic filariasis

KW - neglected tropical diseases

KW - onchocerciasis

KW - phenotypic screening

KW - Wolbachia

U2 - 10.1177/2472555219838341

DO - 10.1177/2472555219838341

M3 - Article

SN - 2472-5552

VL - 24

SP - 537

EP - 547

JO - SLAS Discovery

JF - SLAS Discovery

IS - 5

ER -

Development of a High-Throughput Cytometric Screen to Identify Anti-Wolbachia Compounds: The Power of Public–Private Partnership

Abstract

UN SDGs

Keywords

Access to Document

Fingerprint

Cite this